News & Updates
Filter by Specialty:
Semaglutide scores again, this time for HFpEF in obese
Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.
Semaglutide scores again, this time for HFpEF in obese
03 Oct 2023
Impaired renal function ups cardiovascular risk in young adults
Estimated glomerular filtration rate (eGFR) below age-expected values appears to indicate an increased risk for major adverse cardiovascular events (MACE) and MACE plus heart failure (MACE+) in young adults, according to a study.
Impaired renal function ups cardiovascular risk in young adults
01 Oct 2023
Ultraprocessed food intake ups mortality risk in T2D patients
Individuals with type 2 diabetes (T2D) who regularly consume ultraprocessed foods (UPF), regardless of diet quality, appear to have reduced survival and increased cardiovascular disease (CVD) mortality rate, suggests a recent study.
Ultraprocessed food intake ups mortality risk in T2D patients
01 Oct 2023
Use of 5αRI does not increase cardiovascular risk in men with BPH
Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.
Use of 5αRI does not increase cardiovascular risk in men with BPH
30 Sep 2023
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.
